The Preferred Biotech Resource in Asia-Pacific
Vol 19, No 07, July 2015
Biotech in China
Kh-biotech cover

Featured
Interviews

Eye on China

Columns

Conferences ListingConferences
Listing

e-alerts
Pharma Sales
EYE on CHINA
Partner State Key Laboratory of Pharmaceutical Biotechnology opened at HKU
The Ministry of Science and Technology of the Central Government has approved the application from Li Ka Shing Faculty of Medicine, the University of Hong Kong in July to establish a “Partner State Key Laboratory of Pharmaceutical Biotechnology” at HKU, in strategic collaboration with State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University. The Laboratory aims to conduct basic, clinical and translational research on obesity, diabetes and its cardiovascular complications. This State Key Laboratory is the fifth one set up at HKU which will continue its contribution to the Mainland and local scholarly and research exchanges.

Professor Xu Aimin, Professor of Department of Medicine, Li Ka Shing Faculty of Medicine, HKU is the director of the Laboratory. He says, “ Up to date, about 93 million adults are now suffering from diabetes and over 140 million adults with prediabetes are at high risk to develop overt diabetes in China. Diabetes is not only a major risk factor for cardiovascular disease, but is also causally associated with many types of cancers. These chronic diseases hence impose an enormous medical and economic burden to our society. Development of key research platforms and innovative medicine for diabetes and related chronic diseases are a major strategic emphasis in the national 12th five-year plan of China. The establishment of the Laboratory is believed to foster and bring pivotal result of the researches.”

“The Partner State Key Laboratory of Pharmaceutical Biotechnology”, located at Li Ka Shing Faculty of Medicine, HKU, is run by the Department of Medicine and Department of Pharmacology and Pharmacy. The team of HKU has nearly 80 researchers. The Chinese University of Hong Kong and The Hong Kong University of Science and Technology have formed an interdisciplinary team to participate in the research.

The research team hopes that the establishment of this laboratory will serve as a key platform to strengthen the collaborations and academic exchange with the Mainland and international scientists, and to train young researchers, and to support the pharmaceutical industries as well as clinical practice in Hong Kong and Mainland China.

Click here for the complete issue.